BioTerm Pharmaceuticals
Therapeutics for Preterm Labor Prevention and Labor Induction
Company Overview
Snapshot
Founded in January 2002 by Israel Shamir Lebovitz, BioTerm Pharmaceuticals operates with 1–10 employees. The company holds one patent and is currently in the Pre-Funding stage, seeking equity investment to expand management and enhance marketing and business development activities in the U.S. and Europe.
Business overview
BioTerm Pharmaceuticals is a Health Tech & Life Sciences company focused on developing therapeutics for women's health, specifically for the prevention of preterm labor and the induction of labor. The company's core products, Preventerm and Inducterm, are based on scientifically and clinically proven molecules. Preventerm is designed to block key factors in the labor process, aiming for effective multistep inhibition of enzymes to prevent preterm labor. Inducterm, conversely, works by providing collagenase to induce labor. BioTerm Pharmaceuticals operates within the Pharmaceuticals sector, targeting the healthcare market in Israel and the United States.
Strategic signal
In April 2015, BioTerm Pharmaceuticals was highlighted in an article by Pharmaceutical Intelligence, focusing on Dr. Shamir's startup. This signals the company's early recognition within the pharmaceutical industry for its innovative approach to women's health therapeutics, indicating potential interest from strategic partners or investors in its specialized drug development.
Log in to access full profile ›Company Intelligence Q&A
- What was BioTerm Pharmaceuticals' operational status?
- BioTerm Pharmaceuticals ceased to operate in July 2019, transitioning to a non-active status.
- Who founded BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals was founded by Israel Shamir Lebovitz, who also served as its President and Chief Medical Officer.
- What primary therapeutic areas did BioTerm Pharmaceuticals focus on?
- BioTerm Pharmaceuticals focused on developing therapeutics for the prevention of preterm labor and for the induction of labor.
- What were the key products developed by BioTerm Pharmaceuticals?
- The company developed Preventerm, a patent-pending molecule for preterm labor prevention, and Inducterm, a patented molecule for labor induction.
- What was the company's employee count?
- BioTerm Pharmaceuticals operated with 1–10 employees.